Nephrologists Often Don't Treat Depression in Dialysis Patients

This article originally appeared here.
Share this content:
Nephrologists Often Don't Treat Depression in Dialysis Patients
Nephrologists Often Don't Treat Depression in Dialysis Patients

FRIDAY, Jan. 27, 2017 (HealthDay News) -- Depression is common among kidney failure patients undergoing dialysis, but efforts to get them on antidepressants often fail, according to research published online Jan. 26 in the Clinical Journal of the American Society of Nephrology.

The study included 101 dialysis patients who completed monthly questionnaires about depression symptoms. They were followed for at least one year. Thirty-nine patients were diagnosed with depression, based on assessments from a total of 147 sessions with health care staff.

The researchers found that 70 percent of sessions showed evidence that the patient was getting antidepressant treatment. In 70 percent of cases where a nurse recommended that the patient intensify treatment, the patient refused to do so. In 11 of 18 cases where patients agreed they needed depression medication, renal providers were unwilling to prescribe it. The main reason patients refused to take antidepressants was because they felt their depression was attributable to an acute event, chronic illness, or dialysis.

"Our study demonstrated that many patients on chronic hemodialysis have depressive symptoms but do not wish to receive aggressive treatment to alleviate these symptoms," study co-leader Steven Weisbord, M.D., of the VA Pittsburgh Healthcare System, said in a journal news release. "We also noted that when patients are willing to accept treatment, renal providers commonly do not prescribe treatment."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »